Organogenesis Holdings Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered director elections, executive compensation approval, and auditor ratification, with all proposals passing by the required votes. No additional shareholder proposals were raised, and no questions were submitted during the Q&A session.
-
Q1 2026 saw a 58% revenue decline, mainly from advanced wound care, due to CMS policy changes and market disruption. Despite this, market share improved, restructuring was implemented, and key regulatory milestones were achieved. Sequential recovery and profitability are expected by Q4.
Fiscal Year 2025
-
Record Q4 and 2025 revenue driven by advanced wound care, but 2026 faces a 25%-38% revenue decline due to CMS policy changes and clinician confusion. Management expects recovery and market share gains in the second half of 2026, supported by new investments and product innovation.
-
Q3 2025 revenue and earnings exceeded expectations, led by 31% growth in advanced wound care and 25% in surgical and sports medicine. CMS payment reforms and strong product positioning set the stage for continued growth, with 2025 guidance raised across key metrics.
-
A major regulatory shift will standardize reimbursement and focus competition on clinical efficacy. New product launches and manufacturing expansion are driving growth, with a strong pipeline including ReNu targeting the pain management market. Financials remain solid with a positive outlook.
-
Q2 revenue declined 23% year-over-year, with advanced wound care impacted by regulatory delays and aggressive pricing, while surgical and sports medicine grew 16%. 2025 guidance was tightened, with new CMS payment reforms expected to benefit the business in 2026.
-
Q1 2025 revenue declined 21% year-over-year but met guidance amid LCD policy uncertainty. The company reaffirmed 2025 guidance, expects business improvement in the second half, and is advancing clinical programs and manufacturing expansion.
Fiscal Year 2024
-
Fourth quarter revenue grew 27% year-over-year, exceeding guidance due to strong demand and delayed LCD implementation. FY2025 guidance anticipates a challenging first half from LCD changes, with improvement expected in the second half. Cash position strengthened by a major capital raise.
-
Q3 2024 revenue and earnings exceeded guidance, driven by strong execution and clinical progress. Updated 2024 guidance reflects higher revenue and improved profitability, while ongoing regulatory and reimbursement changes present both risks and long-term opportunities.
-
Leadership highlighted significant growth from a single product to a $25B TAM, driven by innovation and acquisitions. Regulatory changes are reshaping the market, but a strong product portfolio and pipeline, including the promising ReNu program, position the company for future growth.
-
Q2 revenue and gross margin exceeded expectations, driven by strong commercial execution and account growth, while non-cash impairment charges led to a net loss. The ReNu program advanced with positive phase III results and a clear BLA submission path, and robust clinical data was submitted to support product reimbursement.